A Fresh Look at Varonis Systems (VRNS) Valuation After Updated Guidance and SlashNext Acquisition Costs

Varonis Systems (VRNS) just updated its earnings outlook for the third quarter and full year, and investors are sure to take notice. The new guidance calls for revenue growth of 10% to 14% for both the upcoming quarter and the full year, driven partly by the recent acquisition of SlashNext. However, the company is also flagging higher near-term expenses from integrating SlashNext, meaning profit margins could slim a bit before potential synergies kick in. For investors weighing what to do next, these moving pieces spark a fresh debate on where the stock could be headed from here.

This is not the first shakeup for Varonis this year. The launch of its Next-Gen Database Activity Monitoring in July underlines its focus on expanding SaaS and annual recurring revenue streams, even as the company juggles short-term acquisition costs. The market seems to have responded positively overall, with the stock advancing 14% over the past three months and almost 10% in the year. The longer-term story is even stronger, but the pace of momentum has recently picked up as Varonis leans harder into product innovation and strategic deals.

With these recent shifts and ongoing growth in focus, the question remains: is Varonis stock undervalued after the recent guidance, or has the market already priced in future gains?

Advertisement

Most Popular Narrative: 9.8% Undervalued

According to the most widely followed narrative, Varonis Systems is currently trading almost 10% below its fair value. Analysts are forecasting stronger growth potential, supported by sector trends in cybersecurity and the company's ongoing SaaS transition.

SaaS transition, R&D investments, and platform enhancements are boosting recurring revenue, customer retention, and competitive advantage. These factors are strengthening long-term earnings and profitability. At the same time, the shift to SaaS is pressuring revenue, margins, and profits, and is increasing dilution and competitive risks. Growth will also depend on sustained customer expansion in a consolidating industry.

Curious what fuels this undervalued call? This narrative is built on surprisingly bold earnings and margin assumptions, cutting-edge product partnerships, and future growth targets not seen in most sector peers. Want to uncover the growth recipe and ambitious projections that drive this price target? The numbers behind this valuation might change how you see this stock.

Result: Fair Value of $62.43 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, risks such as ongoing margin pressure from the SaaS transition and potential dilution from a rising share count could challenge these optimistic forecasts.

Find out about the key risks to this Varonis Systems narrative.

Another View: Valuation Based on Sales Metrics

Looking at a valuation method based on sales multiples, Varonis actually appears expensive compared to the broader US software industry. While the previous analysis highlights upside, this angle may cast fresh doubts on the story.

See what the numbers say about this price — find out in our valuation breakdown.
NasdaqGS:VRNS PS Ratio as at Sep 2025
NasdaqGS:VRNS PS Ratio as at Sep 2025
Stay updated when valuation signals shift by adding Varonis Systems to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own Varonis Systems Narrative

If you have a different perspective or want to investigate the numbers firsthand, building your own take takes just a few minutes. Do it your way

A great starting point for your Varonis Systems research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More High-Potential Stock Ideas?

Don't limit your strategy to just one company. The market is bursting with fresh opportunities. Use the Simply Wall Street Screener to spot your next big winner before others do.

  • Capture the power of artificial intelligence in your portfolio by targeting companies at the forefront of smart automation and data-driven breakthroughs through AI penny stocks.
  • Maximize your search for value by zeroing in on stocks with robust free cash flows and attractive price tags thanks to undervalued stocks based on cash flows.
  • Secure steady returns for the long haul with shares offering reliable income and above-average payouts via dividend stocks with yields > 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:VRNS

Varonis Systems

Provides software products and services that continuously discover and classify critical data, remediate exposures, and detect advanced threats with AI-powered technology in North America, Europe, APAC, and rest of worlds.

Excellent balance sheet and slightly overvalued.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
48 users have followed this narrative
2 users have commented on this narrative
8 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7720.1% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
83 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
190 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0